Patients with Alzheimer’s disease (AD) had lower plasma Aβ40 and higher plasma Aβ42 and tau protein levels than patients with mild cognitive impairment (MCI) and healthy controls (Chiu et al., 2013, 2014). This evidence concerns the gene MAPT and Alzheimer disease.